BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,514 shares of the company's stock after purchasing an additional 11,325 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in BridgeBio Pharma were worth $1,134,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BBIO. Janus Henderson Group PLC lifted its stake in BridgeBio Pharma by 11.7% in the 3rd quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company's stock valued at $122,658,000 after buying an additional 505,481 shares in the last quarter. First Turn Management LLC acquired a new stake in shares of BridgeBio Pharma during the third quarter valued at $10,178,000. Erste Asset Management GmbH acquired a new stake in shares of BridgeBio Pharma during the third quarter valued at $3,497,000. Massachusetts Financial Services Co. MA raised its stake in BridgeBio Pharma by 23.3% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 737,367 shares of the company's stock valued at $18,773,000 after purchasing an additional 139,104 shares during the last quarter. Finally, Exome Asset Management LLC raised its stake in BridgeBio Pharma by 167.4% in the 3rd quarter. Exome Asset Management LLC now owns 211,000 shares of the company's stock valued at $5,372,000 after purchasing an additional 132,093 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the sale, the insider now owns 19,260,971 shares of the company's stock, valued at $634,841,604.16. The trade was a 23.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 326,932 shares of the stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28. Following the transaction, the chief executive officer now directly owns 5,371,515 shares of the company's stock, valued at approximately $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,579,739 shares of company stock valued at $323,171,901 in the last three months. 24.66% of the stock is currently owned by corporate insiders.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO traded up $0.86 during midday trading on Friday, hitting $34.77. The company's stock had a trading volume of 3,454,003 shares, compared to its average volume of 2,122,866. The firm has a market cap of $6.61 billion, a P/E ratio of -12.20 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47. The firm's fifty day moving average price is $33.96 and its 200-day moving average price is $29.03.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. As a group, research analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BBIO shares. HC Wainwright reaffirmed a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. Evercore ISI lifted their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a research report on Monday, December 23rd. Scotiabank increased their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Friday, February 21st. Finally, Bank of America raised their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $51.55.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.